Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy - The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy - The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial
复制标题
DOI：
10.2337/dc05-2370
复制
发表时间：
2006-07-01
期刊：
影响因子：
16.2
通讯作者：
Shigeta, Yukio
中科院分区：
文献类型：
--
作者：
Hotta, Nigishi;Akanuma, Yasuo;Shigeta, Yukio
目的-我们试图评估依帕司他，一种醛糖还原酶抑制剂，对糖尿病周围神经病变的长期疗效和安全性。研究设计和方法-糖尿病神经病变，运动神经传导速度中位数（MNCV）>= 40 m/s，HbA（1c）
OBJECTIVE - We sought to evaluate the long-term efficacy and safety of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy.RESEARCH DESIGN AND METHODS - Subjects with diabetic neuropathy, median motor nerve conduction velocity (MNCV) >= 40 m/s, and HbA(1c)